Taranjit S. Gujral

This study uses single-nucleus RNA-seq to identify unique neuroepithelial features in canine acanthomatous ameloblastoma, revealing ERBB4 as a therapeutic target.

This study identifies RFX4's role in cortical development by showing it restrains neurogenesis and regulates synaptic gene expression, with distinct effects from haploinsufficiency.

This study identifies MERTK as a therapeutic target in ZFTA-RELA-driven ependymomas through transcriptomic analysis and drug screening.

The paper identifies subtype-specific dependencies and drug vulnerabilities in HNSCC to enable precision therapeutics using transcriptomic and CRISPR data.

The paper constructs a transcriptomic landscape for medulloblastoma and ependymoma, revealing subtype-specific biology through clustering and molecular signatures.

The paper introduces a bioprinting method to precisely place and immobilize microdissected tumor cuboids in hydrogels for drug testing and protein analysis.

This study shows that BET inhibitor treatment rewires Ewing sarcoma transcription, increasing dependency on FAK, and that combining BET and FAK inhibitors synergistically reduces tumor growth.

The paper identifies a specific D4Z4 sequence that can epigenetically silence a reporter gene, revealing key regulators and mechanisms of DUX4 repression in skeletal muscle.

This paper presents a low-cost robotic platform for manipulating live microtissues to enable cancer drug testing using patient biopsies on 384-well plates.

This study uses single-nucleus multi-omics to analyze fibrolamellar carcinoma, revealing rewired cell communication and potential therapeutic targets.

This study develops a microfluidic platform to perfuse microdissected tumors, showing improved microvascular structure and CD31 expression compared to diffusive transport.

The paper develops a microscale ex vivo cancer model using tumor cuboids that retain a complex tumor microenvironment, enabling drug and immunotherapy testing.

KinCytE links kinase inhibitors to cytokine/chemokine signaling networks to identify therapeutic opportunities for difficult-to-drug targets.

The paper identifies Ponatinib as a potent inhibitor of cytokine storm induced by SARS-CoV-2 spike protein NTD in human cells.

The paper presents a dataset of kinase inhibitor profiles and introduces an improved method to identify key kinases involved in cellular phenotypes using quantitative assays and machine learning.